The Oxford Participation and Activities Questionnaire (OxPAQ) has now been validated for other conditions

28th February 2019

The OxPAQ is now validated for use in Chronic obstructive pulmonary disease (COPD), Aneurysmal subarachnoid haemorrhage (AHS) and Valvular heart disease.

The Clinical Outcomes team at Oxford University Innovation are very pleased to announce the expansion of the conditions that the generic Oxford Participation and Activities Questionnaire (OxPAQ) is validated for. When the PROM was launched, evidence was published on the validity of the OxPAQ for application as an outcome measure in studies of Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). We are now pleased to announce that, following further testing, it is now also validated for use in Chronic obstructive pulmonary disease (COPD), Aneurysmal subarachnoid haemorrhage (AHS) and Valvular heart disease.

 

In addition, and due to the increasing adoption of the OxPAQ as a generic outcome measure, the library of available translations has dramatically increased to 28 translations / cultural adaptions for use in 17 countries, including North America, most of Europe, Korea, Australia and New Zealand.

 

Finally, the OxPAQ user manual has also been updated and is now available in its second edition from the Clinical Outcomes team.

 

For more information, please do not hesitate to get in touch with us via healthoutcomes@innovation.ox.ac.uk.

Press release sign up